JPRN-jRCT2071210062已完成1 期
Phase I clinical trial of AKP-009 : A single and multiple dose study at additional doses
Shimomiya Kazuhiro0 个研究点目标入组 45 人开始时间: 2021年9月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •The subjects are capable of understanding the requirements of this protocol and of providing voluntary written informed consent for participation in this study.
- •-Japanese healthy adult male aged 65 years or older in the multiple-dose 20 mg-H group and 20 years through 40 years in the other groups at the time of informed consent
- •-Subjects with a BMI of 18.5 or higher and < 25.0 (rounded down at the second decimal place)at the time of screening
- •-Subjects appropriate for the study as determined by principal investigator or sub-investigator (hereinafter, Investigators) based on screening tests
排除标准
- •-Subjects with a pre-existing or a history of liver disorder, renal disorder, cerebro-cardiovascular disease, gastrointestinal disorder, hematologic disorder, endocrine disease, or other disease that would be inappropriate for this study
- •-Subjects with tendency of drug allergy
- •-Subjects with a pre-existing or history of epilepsy or other convulsive disease
- •-Subjects with a pre-existing or history of alcohol dependence
- •-Subjects with a positive test result for drugs of abuse at the screening test
- •-Subjects whose HBs-antigen, HCV-antibody, HIV antigen/antibody, or serologic test for syphilis is positive at the time of screening
- •-Subjects whose body weight is <50 kg at the time of screening
- •-Subjects undergoing blood draw exceeding 200 mL within 4 weeks or 400 mL within 12 weeks prior to the start of dose in this study, or subjects undergoing pheresis within 2 weeks prior to the start of dose in this study
- •-Subjects inappropriate to take part in this study based on the status of drug use within 1 week prior to the start of dose in this study as determined by the investigators
- •-Subjects who have taken part in other clinical study within 16 weeks before the start of treatment in this study (but within 12 weeks if the investigational product is already approved)
- •-Subjects who received the first dose of vaccination for prevention of new coronavirus infection (COVID-19) within the 2 weeks prior to the screening test
- •-Subjects who is otherwise inappropriate for the study as determined by the investigators
研究者
相似试验
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001AtopyNCT02563938Allakos Inc.34
进行中（未招募）
不适用
AA single-arm Phase II clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelialovarian cancer - OctaviaEpithelial ovarian cancer, falloppian tube or primary peritoneal carcinomaMedDRA version: 9.1Level: LLTClassification code 10033128MedDRA version: 9.1Level: LLTClassification code 10016180MedDRA version: 9.1Level: LLTClassification code 10061344EUCTR2008-008336-85-ITF. Hoffman - La Roche Ltd.180
Unknown
1 期
Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal FunctionType2DiabetesNCT05328843PegBio Co., Ltd.24
已完成
1 期
Phase 1 XG005-03 Topical StudyPainNCT04283474Xgene Pharmaceutical Group36
进行中（未招募）
1 期
Phase I/IIa Clinical Trial of KTP-001 in Subjects with Lumbar Disc HerniatioJPRN-jRCT2031210516Haro Hirotaka23